세계의 감염증 진단 시장 : 제품별 및 서비스별, 검사 유형별, 샘플 유형별, 질환 유형별, 기술별, 임상 용도별, 최종 사용자별, 지역별 예측(-2030년)

The infectious disease diagnostics market is projected to reach USD 42.20 billion by 2030 from USD 26.58 billion in 2025, at a CAGR of 9.7% during the forecast period.

The factors driving the market growth include the increasing emphasis on decentralized diagnostics and the rising demand for CLIA-waived point-of-care (PoC) tests. These trends have significantly contributed to the widespread adoption of PoC technologies. The need for efficient healthcare delivery primarily fuels the shift towards decentralized PoC testing. By relocating diagnostic testing to point-of-care settings, healthcare providers can perform diagnostics directly at the patient's side, minimizing the time between sample collection and results.

By type of testing, the PoC testing segment is expected to grow at the highest CAGR during the forecast period.

By type of testing, the infectious disease diagnostics market is segmented into laboratory and PoC testing. The PoC testing segment is expected to grow at the highest CAGR during the forecast period. The high growth rate of this segment is attributed to the increasing investments from key companies, with a strong emphasis on innovation through product launches & strategic acquisitions. PoC testing offers several advantages over traditional laboratory testing, particularly in clinical & hospital settings. A key benefit of PoC testing is its rapid turnaround time, enabling enhanced diagnostic decisions. Moreover, PoC testing typically requires smaller sample volumes, making it less invasive and efficient.

By technology, the DNA sequencing & next-generation sequencing segment is expected to grow at the highest CAGR during the forecast period.

The infectious disease diagnostics market is segmented into immunodiagnostics, clinical microbiology, polymerase chain reaction, isothermal nucleic acid amplification technology, DNA sequencing & next-generation sequencing, DNA microarray, and other technologies. The DNA sequencing & next-generation sequencing segment is projected to register the highest CAGR during the forecast period. DNA sequencing is a user-friendly platform that is easily implemented in clinical settings to deliver rapid results. Its ability to analyze genetic material has expanded its potential across applications, including personalized medicine, cancer research, and drug discovery. Moreover, advancements in sequencing technologies, broadening applications across multiple domains, and the rising demand for personalized medicine are key factors expected to support the growth of this market segment in the coming years.

By region, the Asia Pacific region is projected to grow at the highest CAGR during the forecast period.

The market is segmented by region into North America, Europe, the Asia Pacific, Latin America, and the Middle East & Africa. The Asia Pacific region is expected to experience the highest growth rate during the forecast period. Emerging economies in this region are seeing consistent GDP growth and a notable rise in disposable income, which has been attributed to rising healthcare spending and the uptake of advanced diagnostics. Additional growth drivers include the rising incidence & prevalence of infectious diseases, modernization of healthcare infrastructure, and the increasing adoption of advanced diagnostic technologies, particularly in rural areas.

The break-up of the profile of primary participants in the infectious disease diagnostics market:

• By Company Type: Tier 1 - 40%, Tier 2 - 30%, and Tier 3 - 30%
• By Designation: C-level - 27%, D-level - 18%, and Others - 55%
• By Region: North America - 51%, Europe - 21%, the Asia Pacific - 18%, Latin America - 6%, and the Middle East & Africa- 4%

The key players in this market are F. Hoffmann-La Roche Ltd. (Switzerland), Abbott (US), Danaher Corporation (US), bioMerieux (France), Thermo Fisher Scientific Inc. (US), Siemens Healthineers AG (Germany), Becton, Dickinson and Company (US), Revvity, Inc. (US), Hologic, Inc. (US), QIAGEN N.V. (Netherlands), Seegene Inc. (South Korea), QuidelOrtho Corporation (US), Grifols, S.A. (Spain), DiaSorin S.p.A (Italy), Bio-Rad Laboratories, Inc. (US), Sysmex Corporation (Japan), OraSure Technologies, Inc. (US), Co-Diagnostics, Inc. (US), SD Biosensor, INC. (South Korea), BIOSYNEX SA (France), Trinity Biotech (Ireland), Bruker (US), Genetic Signatures Ltd. (Australia), Epitope Diagnostics, Inc. (US), Trivitron Healthcare (India), Meril Life Sciences Pvt. Ltd. (India), InBios International, Inc. (US), Unijogen Oy (Finland), Vela Diagnostics (Singapore), and Molbio Diagnostics Limited (India).

Research Coverage:

This research report categorizes the infectious disease diagnostics market by product & service (reagents, kits, and consumables, instruments, and software & services), by type of testing (laboratory testing, PoC testing), by disease type (hepatitis, HIV, hospital-acquired infections, mosquito-borne diseases, HPV, Chlamydia trachomatis, Neisseria gonorrhea, tuberculosis, influenza, syphilis, and other infectious diseases), by sample type (blood, serum, and plasma, urine, and other sample types), by technology (immunodiagnostics, polymerase chain reaction, clinical microbiology, isothermal nucleic acid amplification technology, DNA sequencing & next-generation sequencing, DNA microarray, and other technologies), by clinical application (diagnostics and screening), by end user (diagnostic laboratories, hospitals & clinics, academic research institutes, and other end users), and region (North America, Europe, the Asia Pacific, Latin America, and the Middle East & Africa). The report's scope covers detailed information regarding the major factors, such as drivers, restraints, opportunities, and challenges influencing the growth of the infectious disease diagnostics market. A thorough analysis of the key industry players has provided insights into their business overview, solutions, key strategies, acquisitions, and agreements. New product & service launches and recent infectious disease diagnostics market developments. This report covers the competitive analysis of upcoming startups in the infectious disease diagnostics market ecosystem.

Reasons to Buy this Report:

The report will help the market leaders/new entrants with information on the closest approximations of the revenue numbers for the overall infectious disease diagnostics market and the subsegments. This report will help stakeholders understand the competitive landscape and gain more insights to position their businesses better and plan suitable go-to-market strategies. The report also helps stakeholders understand the market pulse and provides information on key market drivers, restraints, opportunities, and challenges.

The report provides insights into the following pointers:

• Analysis of key drivers (Rising prevalence of infectious diseases, rising focus on R&D and funding investments for infectious disease diagnostic products, adoption of innovative & advanced technologies for infectious disease diagnosis, gradual shift from centralized laboratories to decentralized POC testing centers), opportunities (high growth potential of emerging economies), restraints (unfavorable reimbursements), and challenges (stringent regulatory guidelines for ivd products, operational barriers and shortage of skilled laboratory technicians) influencing the growth of the infectious disease diagnostics market.
• Product Development/Innovation: Detailed insights on upcoming technologies, research & development activities, and new product launches in the infectious disease diagnostics market.
• Market Development: Comprehensive information about lucrative markets - the report analyses the infectious disease diagnostics market across varied regions.
• Market Diversification: Exhaustive information about new products & services, untapped geographies, recent developments, and investments in the infectious disease diagnostics market

Competitive Assessment: In-depth assessment of market shares, growth strategies, and service offerings of leading players like F. Hoffmann-La Roche Ltd. (Switzerland), Abbott (US), Danaher Corporation (US), bioMerieux (France), and Thermo Fisher Scientific Inc. (US), among others, in the infectious disease diagnostics market.

TABLE OF CONTENTS

1 INTRODUCTION

• 1.1 STUDY OBJECTIVES
• 1.2 MARKET DEFINITION
• 1.3 MARKET SCOPE
  • 1.3.1 MARKETS COVERED & REGIONAL SCOPE
  • 1.3.2 INCLUSIONS & EXCLUSIONS
  • 1.3.3 YEARS CONSIDERED
  • 1.3.4 CURRENCY CONSIDERED
• 1.4 KEY STAKEHOLDERS
• 1.5 SUMMARY OF CHANGES

2 RESEARCH METHODOLOGY

• 2.1 RESEARCH DATA
• 2.2 RESEARCH APPROACH
  • 2.2.1 SECONDARY DATA
    • 2.2.1.1 Key secondary sources
    • 2.2.1.2 Key data from secondary sources
  • 2.2.2 PRIMARY DATA
    • 2.2.2.1 Primary sources
    • 2.2.2.2 Key data from primary sources
    • 2.2.2.3 Key industry insights
    • 2.2.2.4 Breakdown of primary interviews
• 2.3 MARKET SIZE ESTIMATION
  • 2.3.1 BOTTOM-UP APPROACH
    • 2.3.1.1 Approach 1: Company revenue estimation approach
    • 2.3.1.2 Approach 2: Presentations of companies and primary interviews
    • 2.3.1.3 Growth forecast
    • 2.3.1.4 CAGR projections
  • 2.3.2 TOP-DOWN APPROACH
• 2.4 MARKET BREAKDOWN AND DATA TRIANGULATION
• 2.5 MARKET SHARE ASSESSMENT
• 2.6 RESEARCH ASSUMPTIONS
  • 2.6.1 PARAMETRIC ASSUMPTIONS
• 2.7 RESEARCH LIMITATIONS
• 2.8 RISK ASSESSMENT

3 EXECUTIVE SUMMARY

4 PREMIUM INSIGHTS

• 4.1 INFECTIOUS DISEASE DIAGNOSTICS MARKET OVERVIEW
• 4.2 INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2025 VS. 2030 (USD MILLION)
• 4.3 INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY TYPE OF TESTING, 2025 VS. 2030 (USD MILLION)
• 4.4 INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY SAMPLE TYPE, 2025 VS. 2030 (USD MILLION)
• 4.5 INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY DISEASE TYPE, 2025 VS. 2030 (USD MILLION)
• 4.6 INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY TECHNOLOGY, 2025 VS. 2030 (USD MILLION)
• 4.7 INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY CLINICAL APPLICATION, 2025 VS. 2030 (USD MILLION)
• 4.8 INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY END USER, 2025 VS. 2030 (USD MILLION)
• 4.9 INFECTIOUS DISEASE DIAGNOSTICS MARKET: GEOGRAPHIC GROWTH OPPORTUNITIES

5 MARKET OVERVIEW

• 5.1 INTRODUCTION
• 5.2 MARKET DYNAMICS
  • 5.2.1 DRIVERS
    • 5.2.1.1 Rising prevalence of infectious diseases
    • 5.2.1.2 Rising focus on R&D and funding investments for infectious disease diagnostic products
    • 5.2.1.3 Adoption of innovative & advanced technologies for infectious disease diagnosis
    • 5.2.1.4 Gradual shift from centralized laboratories to decentralized PoC testing centers
  • 5.2.2 RESTRAINTS
    • 5.2.2.1 Unfavorable reimbursements
  • 5.2.3 OPPORTUNITIES
    • 5.2.3.1 High growth potential of emerging economies
  • 5.2.4 CHALLENGES
    • 5.2.4.1 Stringent regulatory guidelines for IVD products
    • 5.2.4.2 Operational barriers and shortage of skilled laboratory technicians
• 5.3 PRICING ANALYSIS
  • 5.3.1 INDICATIVE SELLING PRICE TREND OF INFECTIOUS DISEASE DIAGNOSTICS PRODUCTS, 2023-2025
  • 5.3.2 INDICATIVE SELLING PRICE TREND OF INFECTIOUS DISEASE TEST KITS & ASSAYS, BY KEY PLAYER,2023-2025
  • 5.3.3 INDICATIVE SELLING PRICE TREND OF INFECTIOUS DISEASE DIAGNOSTIC PRODUCTS, BY REGION, 2023-2025
• 5.4 PATENT ANALYSIS
  • 5.4.1 LIST OF MAJOR PATENTS
• 5.5 VALUE CHAIN ANALYSIS
• 5.6 SUPPLY CHAIN ANALYSIS
• 5.7 TRADE ANALYSIS
  • 5.7.1 TRADE ANALYSIS FOR DIAGNOSTIC & LABORATORY REAGENTS
  • 5.7.2 IMPORT DATA (HS CODE 3822)
  • 5.7.3 EXPORT DATA (HS CODE 3822)
• 5.8 ECOSYSTEM ANALYSIS
  • 5.8.1 INFECTIOUS DISEASE DIAGNOSTICS MARKET: ROLE IN ECOSYSTEM
• 5.9 PORTER'S FIVE FORCES ANALYSIS
  • 5.9.1 THREAT OF NEW ENTRANTS
  • 5.9.2 THREAT OF SUBSTITUTES
  • 5.9.3 BARGAINING POWER OF BUYERS
  • 5.9.4 BARGAINING POWER OF SUPPLIERS
  • 5.9.5 INTENSITY OF COMPETITIVE RIVALRY
• 5.10 REGULATORY LANDSCAPE
  • 5.10.1 REGULATORY FRAMEWORK
    • 5.10.1.1 North America
      • 5.10.1.1.1 US
      • 5.10.1.1.2 Canada
    • 5.10.1.2 Europe
      • 5.10.1.2.1 Germany
      • 5.10.1.2.2 UK
      • 5.10.1.2.3 France
      • 5.10.1.2.4 Italy
    • 5.10.1.3 Asia Pacific
      • 5.10.1.3.1 China
      • 5.10.1.3.2 Japan
      • 5.10.1.3.3 India
    • 5.10.1.4 Latin America
      • 5.10.1.4.1 Brazil
      • 5.10.1.4.2 Mexico
    • 5.10.1.5 Middle East
      • 5.10.1.5.1 Africa
  • 5.10.2 REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
• 5.11 TECHNOLOGY ANALYSIS
  • 5.11.1 KEY TECHNOLOGIES
    • 5.11.1.1 Immunodiagnostics
  • 5.11.2 COMPLEMENTARY TECHNOLOGIES
    • 5.11.2.1 Polymerase Chain Reaction (PCR)
  • 5.11.3 ADJACENT TECHNOLOGIES
    • 5.11.3.1 Next-generation Sequencing (NGS)
• 5.12 KEY CONFERENCES & EVENTS, 2025-2026
• 5.13 TRENDS/DISRUPTIONS IMPACTING CUSTOMERS' BUSINESSES
• 5.14 KEY STAKEHOLDERS & BUYING CRITERIA
  • 5.14.1 KEY STAKEHOLDERS IN BUYING PROCESS
  • 5.14.2 BUYING CRITERIA
• 5.15 INVESTMENT & FUNDING SCENARIO
• 5.16 CASE STUDY ANALYSIS
  • 5.16.1 CASE STUDY 1: IMPLEMENTING RAPID PCR TESTING TO IMPROVE NOROVIRUS DIAGNOSIS & BED MANAGEMENT
  • 5.16.2 CASE STUDY 2: USING MOLECULAR DIAGNOSTICS TO IDENTIFY ATYPICAL RESPIRATORY INFECTIONS
  • 5.16.3 CASE STUDY 3: RAPID DIFFERENTIATION OF VIRAL & BACTERIAL INFECTION IN PEDIATRIC PATIENTS
• 5.17 IMPACT OF AI/GENERATIVE AI ON INFECTIOUS DISEASE DIAGNOSTICS MARKET
  • 5.17.1 INTRODUCTION
  • 5.17.2 MARKET POTENTIAL OF AI
  • 5.17.3 AI-USE CASES
  • 5.17.4 IMPLEMENTATION OF AI, BY KEY COMPANY & CASE
  • 5.17.5 FUTURE OF AI IN INFECTIOUS DISEASE DIAGNOSTICS MARKET
• 5.18 TRUMP TARIFF IMPACT ON INFECTIOUS DISEASE DIAGNOSTICS MARKET
  • 5.18.1 INTRODUCTION
  • 5.18.2 KEY TARIFF RATES
  • 5.18.3 PRICE IMPACT ANALYSIS
  • 5.18.4 KEY IMPACT ON COUNTRY/REGION
    • 5.18.4.1 North America
    • 5.18.4.2 Europe
    • 5.18.4.3 Asia Pacific
  • 5.18.5 IMPACT ON END-USE INDUSTRIES
    • 5.18.5.1 Diagnostic laboratories
    • 5.18.5.2 Hospitals & clinics
    • 5.18.5.3 Academic research institutes

6 INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY PRODUCT & SERVICE

• 6.1 INTRODUCTION
• 6.2 REAGENTS, KITS, AND CONSUMABLES
  • 6.2.1 RECURRENT PURCHASE TO PROPEL MARKET
• 6.3 INSTRUMENTS
  • 6.3.1 RAPID TECHNOLOGICAL ADVANCEMENTS FOR ADVANCED ACCURACY TO DRIVE MARKET
• 6.4 SOFTWARE & SERVICES
  • 6.4.1 INCREASING FOCUS ON VALUE-ADDED SERVICES TO SUPPORT MARKET GROWTH

7 INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY TYPE OF TESTING

• 7.1 INTRODUCTION
• 7.2 LABORATORY TESTING
  • 7.2.1 HIGHER SENSITIVITY & SPECIFICITY TO FUEL UPTAKE
• 7.3 POC TESTING
  • 7.3.1 RAPID TURNAROUND TIME AND INCREASING CLIA APPROVALS FOR POC TESTS TO PROPEL MARKET

8 INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY SAMPLE TYPE

• 8.1 INTRODUCTION
• 8.2 BLOOD, SERUM, AND PLASMA
  • 8.2.1 HIGHER VERSATILITY, ENHANCED CLINICAL EFFICACY, AND IMPROVED REIMBURSEMENT POLICIES TO DRIVE MARKET
• 8.3 URINE
  • 8.3.1 NON-INVASIVE NATURE AND ENHANCED PATIENT CONVENIENCE TO BOOST DEMAND
• 8.4 OTHER SAMPLE TYPES

9 INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY DISEASE TYPE

• 9.1 INTRODUCTION
• 9.2 HEPATITIS
  • 9.2.1 HEPATITIS B
    • 9.2.1.1 Highly contagious infection and requirement for regular monitoring to fuel market
  • 9.2.2 HEPATITIS C
    • 9.2.2.1 Rising incidence of chronic HCV and supportive government initiatives to drive market
  • 9.2.3 OTHER HEPATITIS DISEASES
• 9.3 HIV
  • 9.3.1 INCREASING PREVALENCE OF AIDS TO BOOST DEMAND
• 9.4 HOSPITAL-ACQUIRED INFECTIONS
  • 9.4.1 RISING BURDEN OF MRSA INFECTIONS TO FUEL MARKET
• 9.5 MOSQUITO-BORNE DISEASES
  • 9.5.1 RISING INCIDENCE OF DENGUE & MALARIA TO PROPEL MARKET
• 9.6 HPV
  • 9.6.1 RAPID TECHNOLOGICAL ADVANCES TO BOOST DEMAND
• 9.7 CHLAMYDIA TRACHOMATIS
  • 9.7.1 INCREASING AWARENESS INITIATIVES TO SUPPORT MARKET UPTAKE
• 9.8 NEISSERIA GONORRHEA
  • 9.8.1 RISING INCIDENCE OF GONORRHEA TO FUEL MARKET
• 9.9 TUBERCULOSIS
  • 9.9.1 INCREASING BURDEN OF TB IN UNDERSERVED AREAS TO DRIVE MARKET
• 9.10 INFLUENZA
  • 9.10.1 INCREASING FOCUS ON RAPID DIAGNOSIS USING POC TESTING METHODS TO FUEL MARKET
• 9.11 SYPHILIS
  • 9.11.1 IMPROVED SCREENING TECHNOLOGIES TO SUPPORT MARKET UPTAKE
• 9.12 OTHER INFECTIOUS DISEASES

10 INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY TECHNOLOGY

• 10.1 INTRODUCTION
• 10.2 IMMUNODIAGNOSTICS
  • 10.2.1 RISING PREVALENCE OF INFECTIOUS DISEASES AND DEMAND FOR RAPID DIAGNOSTIC KITS TO DRIVE MARKET
• 10.3 CLINICAL MICROBIOLOGY
  • 10.3.1 RAPID TURNAROUND TIME WITH HIGHER SENSITIVITY & RELIABLE RESULTS TO BOOST DEMAND
• 10.4 POLYMERASE CHAIN REACTION
  • 10.4.1 CONVENIENCE & COST-EFFECTIVENESS TO FUEL UPTAKE
• 10.5 ISOTHERMAL NUCLEIC ACID AMPLIFICATION TECHNOLOGY
  • 10.5.1 ENHANCED SUITABILITY FOR POC TESTING WITH LOW-COST FEATURES TO FUEL UPTAKE
• 10.6 DNA SEQUENCING & NEXT-GENERATION SEQUENCING
  • 10.6.1 ADVANCEMENTS IN SEQUENCING TECHNOLOGIES AND RISING FOCUS ON MOLECULAR TARGETED DRUGS TO PROPEL MARKET
• 10.7 DNA MICROARRAY
  • 10.7.1 HIGH INSTRUMENT COSTS TO LIMIT MARKET
• 10.8 OTHER TECHNOLOGIES

11 INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY CLINICAL APPLICATION

• 11.1 INTRODUCTION
• 11.2 DIAGNOSTICS
  • 11.2.1 INCREASING CLINICAL NEED FOR CONFIRMATORY TESTING & TIMELY TREATMENT TO DRIVE MARKET
• 11.3 SCREENING
  • 11.3.1 GROWING IMPORTANCE OF EARLY DISEASE DETECTION TO FUEL MARKET

12 INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY END USER

• 12.1 INTRODUCTION
• 12.2 DIAGNOSTIC LABORATORIES
  • 12.2.1 ABILITY TO CATER TO HIGH-END SPECIALTY TESTING TO PROPEL MARKET
• 12.3 HOSPITALS & CLINICS
  • 12.3.1 IMPROVED REIMBURSEMENTS AND CAPABILITY OF PURCHASING ADVANCED EQUIPMENT TO DRIVE MARKET
• 12.4 ACADEMIC RESEARCH INSTITUTES
  • 12.4.1 INCREASING R&D FUNDING INVESTMENTS TO FUEL MARKET
• 12.5 OTHER END USERS

13 INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY REGION

• 13.1 INTRODUCTION
• 13.2 NORTH AMERICA
  • 13.2.1 NORTH AMERICA: MACROECONOMIC OUTLOOK
  • 13.2.2 US
    • 13.2.2.1 High healthcare expenditure to drive market
  • 13.2.3 CANADA
    • 13.2.3.1 Supportive government initiatives for infectious disease prevention to fuel market
• 13.3 EUROPE
  • 13.3.1 EUROPE: MACROECONOMIC OUTLOOK
  • 13.3.2 GERMANY
    • 13.3.2.1 High adoption of advanced technologies to propel market
  • 13.3.3 UK
    • 13.3.3.1 Increasing number of diagnostic centers to fuel uptake
  • 13.3.4 FRANCE
    • 13.3.4.1 Rising expenditure on life sciences R&D to drive market
  • 13.3.5 ITALY
    • 13.3.5.1 Rising incidence of chronic diseases to boost demand
  • 13.3.6 SPAIN
    • 13.3.6.1 High prevalence of HIV and consolidation of diagnostic laboratories to drive market
  • 13.3.7 REST OF EUROPE
• 13.4 ASIA PACIFIC
  • 13.4.1 ASIA PACIFIC: MACROECONOMIC OUTLOOK
  • 13.4.2 CHINA
    • 13.4.2.1 Increasing burden of hepatitis B virus cases and growing government focus on health surveillance to drive market
  • 13.4.3 JAPAN
    • 13.4.3.1 Presence of established healthcare system and universal reimbursement policies to fuel uptake
  • 13.4.4 INDIA
    • 13.4.4.1 High prevalence of TB & HIV to propel market
  • 13.4.5 REST OF ASIA PACIFIC
• 13.5 LATIN AMERICA
  • 13.5.1 LATIN AMERICA: MACROECONOMIC OUTLOOK
  • 13.5.2 BRAZIL
    • 13.5.2.1 Rising focus on initiating public-private investments for healthcare improvement to fuel uptake
  • 13.5.3 MEXICO
    • 13.5.3.1 Improving accessibility & affordability of healthcare services to support market growth
  • 13.5.4 REST OF LATIN AMERICA
• 13.6 MIDDLE EAST & AFRICA
  • 13.6.1 MIDDLE EAST & AFRICA: MACROECONOMIC OUTLOOK
  • 13.6.2 KINGDOM OF SAUDI ARABIA (KSA)
    • 13.6.2.1 Integration of digital health systems and improvements in healthcare infrastructure to fuel market
  • 13.6.3 UNITED ARAB EMIRATES (UAE)
    • 13.6.3.1 Rising requirement of high-quality healthcare services to support market growth
  • 13.6.4 REST OF MIDDLE EAST & AFRICA

14 COMPETITIVE LANDSCAPE

• 14.1 INTRODUCTION
• 14.2 KEY PLAYER STRATEGIES/RIGHT TO WIN
  • 14.2.1 OVERVIEW OF STRATEGIES DEPLOYED BY PLAYERS IN INFECTIOUS DISEASE DIAGNOSTICS MARKET
• 14.3 REVENUE SHARE ANALYSIS, 2022-2024
• 14.4 MARKET SHARE ANALYSIS, 2024
• 14.5 COMPANY EVALUATION MATRIX: KEY PLAYERS, 2024
  • 14.5.1 STARS
  • 14.5.2 EMERGING LEADERS
  • 14.5.3 PERVASIVE PLAYERS
  • 14.5.4 PARTICIPANTS
  • 14.5.5 COMPANY FOOTPRINT: KEY PLAYERS, 2024
    • 14.5.5.1 Company footprint
    • 14.5.5.2 Region footprint
    • 14.5.5.3 Product & Service footprint
    • 14.5.5.4 Type of testing footprint
    • 14.5.5.5 Sample type footprint
• 14.6 COMPANY EVALUATION MATRIX: STARTUPS/SMES, 2024
  • 14.6.1 PROGRESSIVE COMPANIES
  • 14.6.2 RESPONSIVE COMPANIES
  • 14.6.3 DYNAMIC COMPANIES
  • 14.6.4 STARTING BLOCKS
  • 14.6.5 COMPANY EVALUATION MATRIX: STARTUPS/SMES, 2024
    • 14.6.5.1 Detailed list of key startups/SMEs
    • 14.6.5.2 Competitive benchmarking of startups/SMEs (1/2)
    • 14.6.5.3 Competitive benchmarking of startups/SMEs (2/2)
• 14.7 COMPANY VALUATION & FINANCIAL METRICS
  • 14.7.1 FINANCIAL METRICS
  • 14.7.2 COMPANY VALUATION
• 14.8 BRAND/PRODUCT COMPARISON
  • 14.8.1 BRAND/PRODUCT COMPARATIVE ANALYSIS
• 14.9 COMPETITIVE SCENARIO
  • 14.9.1 PRODUCT/SERVICES LAUNCHES & APPROVALS
  • 14.9.2 DEALS
  • 14.9.3 EXPANSIONS

15 COMPANY PROFILES

• 15.1 KEY PLAYERS
  • 15.1.1 F. HOFFMANN-LA ROCHE LTD.
    • 15.1.1.1 Business overview
    • 15.1.1.2 Products/Services offered
    • 15.1.1.3 Recent developments
      • 15.1.1.3.1 Product/Service launches & approvals
      • 15.1.1.3.2 Deals
      • 15.1.1.3.3 Expansions
    • 15.1.1.4 MnM view
      • 15.1.1.4.1 Key strengths
      • 15.1.1.4.2 Strategic choices
      • 15.1.1.4.3 Weaknesses & competitive threats
  • 15.1.2 ABBOTT
    • 15.1.2.1 Business overview
    • 15.1.2.2 Products/Services offered
    • 15.1.2.3 Recent developments
      • 15.1.2.3.1 Product/Service launches & approvals
      • 15.1.2.3.2 Deals
    • 15.1.2.4 MnM view
      • 15.1.2.4.1 Key strengths
      • 15.1.2.4.2 Strategic choices
      • 15.1.2.4.3 Weaknesses & competitive threats
  • 15.1.3 DANAHER CORPORATION
    • 15.1.3.1 Business overview
    • 15.1.3.2 Products/Services offered
    • 15.1.3.3 Recent developments
      • 15.1.3.3.1 Product/Service launches & approvals
      • 15.1.3.3.2 Deals
      • 15.1.3.3.3 Expansions
    • 15.1.3.4 MnM view
      • 15.1.3.4.1 Key strengths
      • 15.1.3.4.2 Strategic choices
      • 15.1.3.4.3 Weaknesses & competitive threats
  • 15.1.4 BIOMERIEUX
    • 15.1.4.1 Business overview
    • 15.1.4.2 Products/Services offered
    • 15.1.4.3 Recent developments
      • 15.1.4.3.1 Product/Service launches & approvals
      • 15.1.4.3.2 Deals
    • 15.1.4.4 MnM view
      • 15.1.4.4.1 Key strengths
      • 15.1.4.4.2 Strategic choices
      • 15.1.4.4.3 Weaknesses & competitive threats
  • 15.1.5 THERMO FISHER SCIENTIFIC INC.
    • 15.1.5.1 Business overview
    • 15.1.5.2 Products/Services offered
    • 15.1.5.3 Recent developments
      • 15.1.5.3.1 Product/Service launches & approvals
      • 15.1.5.3.2 Deals
    • 15.1.5.4 MnM view
      • 15.1.5.4.1 Key strengths
      • 15.1.5.4.2 Strategic choices
      • 15.1.5.4.3 Weaknesses & competitive threats
  • 15.1.6 SIEMENS HEALTHINEERS AG
    • 15.1.6.1 Business overview
    • 15.1.6.2 Products/Services offered
    • 15.1.6.3 Recent developments
      • 15.1.6.3.1 Product/Service launches & approvals
      • 15.1.6.3.2 Deals
      • 15.1.6.3.3 Expansions
  • 15.1.7 HOLOGIC, INC.
    • 15.1.7.1 Business overview
    • 15.1.7.2 Products/Services offered
    • 15.1.7.3 Recent developments
      • 15.1.7.3.1 Product/Service launches & approvals
      • 15.1.7.3.2 Deals
  • 15.1.8 BECTON, DICKINSON AND COMPANY (BD)
    • 15.1.8.1 Business overview
    • 15.1.8.2 Products/Services offered
    • 15.1.8.3 Recent developments
      • 15.1.8.3.1 Product/Service launches & approvals
      • 15.1.8.3.2 Deals
      • 15.1.8.3.3 Expansions
  • 15.1.9 REVVITY, INC.
    • 15.1.9.1 Business overview
    • 15.1.9.2 Products/Services offered
    • 15.1.9.3 Recent developments
      • 15.1.9.3.1 Product/Service launches & approvals
  • 15.1.10 QIAGEN N.V.
    • 15.1.10.1 Business overview
    • 15.1.10.2 Products/Services offered
    • 15.1.10.3 Recent developments
      • 15.1.10.3.1 Product/Service launches & approvals
      • 15.1.10.3.2 Deals
      • 15.1.10.3.3 Expansions
  • 15.1.11 SEEGENE INC.
    • 15.1.11.1 Business overview
    • 15.1.11.2 Products/Services offered
    • 15.1.11.3 Recent developments
      • 15.1.11.3.1 Product/Service launches & approvals
      • 15.1.11.3.2 Deals
      • 15.1.11.3.3 Expansions
• 15.2 OTHER PLAYERS
  • 15.2.1 QUIDELORTHO CORPORATION
  • 15.2.2 GRIFOLS, S.A.
  • 15.2.3 DIASORIN S.P.A
  • 15.2.4 BIO-RAD LABORATORIES, INC.
  • 15.2.5 SYSMEX CORPORATION
  • 15.2.6 ORASURE TECHNOLOGIES, INC.
  • 15.2.7 CO-DIAGNOSTICS, INC.
  • 15.2.8 SD BIOSENSOR, INC.
  • 15.2.9 BIOSYNEX SA
  • 15.2.10 TRINITY BIOTECH
  • 15.2.11 BRUKER (ELITECHGROUP)
  • 15.2.12 GENETIC SIGNATURES
  • 15.2.13 EPITOPE DIAGNOSTICS, INC.
  • 15.2.14 TRIVITRON HEALTHCARE
  • 15.2.15 MERIL LIFE SCIENCES PVT. LTD.
  • 15.2.16 INBIOS INTERNATIONAL, INC.
  • 15.2.17 UNIOGEN OY
  • 15.2.18 VELA DIAGNOSTICS
  • 15.2.19 MOLBIO DIAGNOSTICS LIMITED

16 APPENDIX

• 16.1 DISCUSSION GUIDE
• 16.2 KNOWLEDGESTORE: MARKETSANDMARKETS' SUBSCRIPTION PORTAL
• 16.3 CUSTOMIZATION OPTIONS
• 16.4 RELATED REPORTS
• 16.5 AUTHOR DETAILS